Decibel Therapeutics, Inc. (DBTX) Financial Statements (2024 and earlier)

Company Profile

Business Address 1325 BOYLSTON STREET
BOSTON, MA 02215
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

6/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments104,561148,747
Cash and cash equivalents34,60736,455
Short-term investments69,954112,292
Restricted cash and investments 38 
Receivables  11,402
Other undisclosed current assets3,4314,042
Total current assets:108,030164,191
Noncurrent Assets
Finance lease, right-of-use asset, after accumulated amortization34 
Operating lease, right-of-use asset9,859 
Property, plant and equipment4,5265,611
Long-term investments and receivables  13,547
Long-term investments  13,547
Other noncurrent assets9241,128
Total noncurrent assets:15,34320,286
TOTAL ASSETS:123,373184,477
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,0045,427
Accounts payable1,0644,012
Accrued liabilities4,9401,415
Debt19200
Other undisclosed current liabilities16,41914,911
Total current liabilities:22,44220,538
Noncurrent Liabilities
Long-term debt and lease obligation  
Finance lease, liability  
Liabilities, other than long-term debt12,3731,611
Other liabilities1,9061,611
Operating lease, liability10,467 
Other undisclosed noncurrent liabilities6,76520,639
Total noncurrent liabilities:19,13822,250
Total liabilities:41,58042,788
Equity
Equity, attributable to parent81,793141,689
Common stock2525
Additional paid in capital359,508356,308
Accumulated other comprehensive loss(223)(132)
Accumulated deficit(277,517)(214,512)
Total equity:81,793141,689
TOTAL LIABILITIES AND EQUITY:123,373184,477

Income Statement (P&L) ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
Revenues
(Sublease Income)
2,476 
Gross profit:2,476 
Operating expenses(63,957)(50,231)
Other undisclosed operating loss(2,476) 
Operating loss:(63,957)(50,231)
Nonoperating income1,192205
Investment income, nonoperating1,192193
Interest and debt expense(14) 
Loss from continuing operations before equity method investments, income taxes:(62,779)(50,026)
Other undisclosed income from continuing operations before income taxes14 
Loss from continuing operations before income taxes:(62,765)(50,026)
Income tax expense(240)(1,797)
Loss from continuing operations:(63,005)(51,823)
Loss before gain (loss) on sale of properties:(51,823)
Net loss attributable to parent:(63,005)(51,823)
Preferred stock dividends and other adjustments  (2,309)
Net loss available to common stockholders, diluted:(63,005)(54,132)

Comprehensive Income ($ in thousands)

6/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(63,005)(51,823)
Comprehensive loss:(63,005)(51,823)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(91)(131)
Comprehensive loss, net of tax, attributable to parent:(63,096)(51,954)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: